Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMORINEPH: Memory B cell level-based tailored Rixathon in complicated steroid-sensitive nephrotic syndrome
2024-511214-20-00Phase 2Withdrawn
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in idiopathic steroid-sensitive nephrotic syndrome (SSNS) (2 arms), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Number of rituximab (RTX) re-infusions over 24 months. Planned start Oct 2024; status: withdrawn.
02
Drugs
rituximab
03
Conditions
idiopathic steroid-sensitive nephrotic syndrome (SSNS)
Beyond the preview
Go deeper on 2024-511214-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511214-20-00.